U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
8505185051A Pharmacokinetics and Safety Study in Subjects With Renal ImpairmentCompletedNo Results AvailableRenal ImpairmentDrug: TR-701 FA single infusion|Drug: TR-701 FA|Drug: TR-701 FAhttps://ClinicalTrials.gov/show/NCT01452828
8505285052Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic GastroparesisCompletedNo Results AvailableGastroparesis|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2Drug: Placebo|Drug: 10mg TZP-102|Drug: 20mg TZP-102https://ClinicalTrials.gov/show/NCT01452815
8505385053Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical ManagementActive, not recruitingNo Results AvailableHeart FailureDevice: HM II (HeartMate II LVAD)|Drug: OMM (Optimal Medical Management)https://ClinicalTrials.gov/show/NCT01452802
8505485054Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence SyndromeRecruitingNo Results AvailableNeonatal Abstinence SyndromeDrug: sublingual buprenorphine|Drug: oral morphinehttps://ClinicalTrials.gov/show/NCT01452789
8505585055Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive EsophagitisCompletedNo Results AvailableErosive EsophagitisDrug: TAK-438|Drug: TAK-438https://ClinicalTrials.gov/show/NCT01452776
8505685056Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose AspirinCompletedNo Results AvailableGastric Ulcers|Duodenal UlcersDrug: TAK-438|Drug: Placebo|Drug: TAK-438|Drug: Placebo|Drug: Lansoprazole|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452763
8505785057Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)CompletedNo Results AvailableGastric Ulcers|Duodenal UlcersDrug: TAK-438|Drug: Placebo|Drug: TAK-438|Drug: Placebo|Drug: Lansoprazole|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452750
8505885058Comparing 4L Golytely to 2L Golytely With 15mg Bisacodyl Regimens for Inpatient Colonic PreparationWithdrawnNo Results AvailableColonoscopyDrug: Standard Bowel Prep|Drug: 2L Golytely/bisacodylhttps://ClinicalTrials.gov/show/NCT01452737
8505985059Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal UlcerCompletedNo Results AvailableDuodenal UlcerDrug: TAK-438|Drug: Placebo|Drug: Lansoprazole|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452724
8506085060Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric UlcerCompletedNo Results AvailableGastric UlcerDrug: TAK-438|Drug: Placebo|Drug: Lansoprazole|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452711
8506185061Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive EsophagitisCompletedNo Results AvailableErosive EsophagitisDrug: TAK-438|Drug: Placebo|Drug: Lansoprazole|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452698
8506285062A Long-term Extension Study of TAK-385 in the Treatment of EndometriosisCompletedNo Results AvailableEndometriosisDrug: Placebo|Drug: TAK-385|Drug: TAK-385|Drug: TAK-385|Drug: Leuprorelin acetatehttps://ClinicalTrials.gov/show/NCT01452685
8506385063Resource-sparing Post-mastectomy Radiotherapy in Breast CancerRecruitingNo Results AvailableBreast CancerRadiation: Radiotherapy|Radiation: Irradiation of the chest-wall and supraclavicular fossahttps://ClinicalTrials.gov/show/NCT01452672
8506485064Efficacy and Safety of TAK-385 in the Treatment of Uterine FibroidsCompletedNo Results AvailableUterine FibroidsDrug: TAK-385|Drug: TAK-385|Drug: TAK-385|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452659
8506585065Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNo Results AvailableAcute Myeloid LeukemiaOther: Risk-adapted, MRD-directed therapyhttps://ClinicalTrials.gov/show/NCT01452646
8506685066Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During LaparoscopyRecruitingNo Results AvailablePost Operative PainDrug: 0.25% bupivicaine will be injected at the study port site prior to incision|Drug: Saline will be injected at the study port site prior to incision|Drug: Saline will be in injected into the port site prior to closure|Drug: 0.25% bupivicaine will be injected into the port site prior to closurehttps://ClinicalTrials.gov/show/NCT01452633
8506785067Endovascular Abdominal Aortic Aneurysm Repair by Interventional CardiologistsCompletedNo Results AvailableEndovascular Abdominal Aortic Aneurysm Repair (EVAR)https://ClinicalTrials.gov/show/NCT01452620
8506885068Study to Evaluate the Safety and Pharmacokinetics of SPI-1005CompletedNo Results AvailableHearing Loss|CancerDrug: SPI-1005|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452607
8506985069Analysis of Diphenylcyclopropenone (DPCP) in NormalsCompletedNo Results AvailableHealthy VolunteersDrug: Diphenylcyclopropenone|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452594
8507085070Liberal Versus Restrictive Transfusion During Symptomatic Moderate Anemia After Hip ArthroplastyTerminatedNo Results AvailableArthroplasty, HipOther: Red blood cell transfusion|Drug: Voluvenhttps://ClinicalTrials.gov/show/NCT01452581
8507185071Anticoagulant After Implantation of Biological Aortic Valve Comparing With AspirinCompletedNo Results AvailableThromboembolism|BleedingDrug: Aspirin|Drug: Warfarinhttps://ClinicalTrials.gov/show/NCT01452568
8507285072Video-Based Delivery of HIV Test Information for Spanish-Speaking LatinosRecruitingNo Results AvailableHIV|AIDSBehavioral: Video or In-Person Presentationhttps://ClinicalTrials.gov/show/NCT01452555
8507385073A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult SubjectsCompletedNo Results AvailableHealthy VolunteerDrug: Eliglustat, common blend proposed commercial formulation|Drug: Eliglustat, Phase 3 capsule formulationhttps://ClinicalTrials.gov/show/NCT01452542
8507485074Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back PainCompletedHas ResultsChronic Low Back PainDrug: Hydrocodone bitartrate q24h film-coated tablets|Drug: Placebo to match hydrocodone bitartrate q24h tabletshttps://ClinicalTrials.gov/show/NCT01452529
8507585075Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter FusionsTerminatedNo Results AvailableDegenerative Disc Disease|Spinal Stenosis|SpondylolisthesisDevice: nanOss Bioactive BVFhttps://ClinicalTrials.gov/show/NCT01452516
8507685076Preference Among 3 Female CondomsCompletedNo Results AvailableFemale CondomDevice: Path Female Condom|Device: FC2 female condom|Device: Medtech female condomhttps://ClinicalTrials.gov/show/NCT01452503
8507785077Diode Laser Treatment of OnychomycosisCompletedNo Results AvailableOnychomycosisDevice: Diode Laser Treatmenthttps://ClinicalTrials.gov/show/NCT01452490
8507885078Tanshinone in Polycystic Ovary SyndromeRecruitingNo Results AvailablePolycystic Ovary SyndromeDrug: tanshinone|Drug: tanshinone placebohttps://ClinicalTrials.gov/show/NCT01452477
8507985079Safety of MenACWY-CRM Vaccination in AdolescentsCompletedNo Results AvailableMeningococcal DiseaseBiological: MenACWY-CRMhttps://ClinicalTrials.gov/show/NCT01452464
8508085080Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusCompletedNo Results AvailableDiabetes MellitusDrug: HM11260C|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01452451

* Görseller ve İçerik tekif hakkına sahip olabilir